Results 61 to 70 of about 19,727 (209)
Hepatitis C virus resistance to the new direct-acting antivirals [PDF]
, 2016 Introduction: The treatment of hepatitis C virus (HCV) infection has dramatically improved in recent years with the widespread use of interferon-free combination regimens.
Esposito, Isabella +2 more
core +1 more source
DEN Open, Volume 6, Issue 1, April 2026.Abstract While hepatocellular carcinoma (HCC) often invades the portal or hepatic vein to form tumor thrombus, tumor thrombus in the bile duct is rare. In such cases, differentiation from intrahepatic cholangiocarcinoma is difficult, and the tumor often appears as a smooth, yellowish‐white, polypoid mass within the bile duct lumen.
Keisuke Kinoshita +9 more
wiley +1 more source
Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR [PDF]
, 2019 The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who ...
Berenguer, Juan +14 more
core +4 more sources
Journal of Viral Hepatitis, Volume 33, Issue 4, April 2026.ABSTRACT Approximately 8.8 million people are living with chronic hepatitis C virus (HCV) in Pakistan. We assessed factors related to health‐related quality of life (HRQoL) among the general population screened for HCV and calculated the national burden in quality‐adjusted life years (QALYs).
Siwaporn Niyomsri +24 more
wiley +1 more source
Journal of Viral Hepatitis, Volume 33, Issue 4, April 2026.ABSTRACT Prisons offer a critical opportunity for hepatitis C virus (HCV) elimination, yet current data from Danish correctional facilities are sparse. We conducted a cross‐sectional study in 16 prisons across Eastern Denmark between October 2022 and August 2024, enrolling 651 incarcerated individuals.
Jonas Demant +10 more
wiley +1 more source
Canadian Journal of Gastroenterology and Hepatology, 2016 Background and Aim. This is an open label prospective cohort study conducted at a tertiary care hospital. The primary endpoint is SVR12 in patients treated with sofosbuvir-based therapy in post-liver transplant patients with genotype 4 HCV recurrence ...
A. Ajlan +8 more
doaj +1 more source
Biomedical and Biotechnology Research Journal, 2022 Background: Hepatitis C virus (HCV) is the most important virus among the infectious agents as the cause of liver disease in Egypt. The aim of this work was to assess the efficacy and tolerability of the sofosbuvir + daclatasvir (±) ribavirin (SOF + DCV [
Hany Mohammed Ibrahim +3 more
doaj +1 more source
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. [PDF]
, 2013 Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C virus (HCV) will become a reality in the near future. In replacing interferon-based therapies, all-oral regimens are expected to be more tolerable, more effective, shorter ...
Afdhal, NH +17 more
core +2 more sources
Rituximab-Containing Treatment Regimens May Imply a Long-Term Risk for Difficult-To-Treat Chronic Hepatitis E [PDF]
, 2020 Hepatitis E virus (HEV) infection is an emerging disease in industrialized countries which is usually characterized by a self-limited course. However, there is an increased risk of HEV persistence in immunocompromised risk populations, comprising ...
Biedermann, Paula +7 more
core +1 more source
A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019
New Microbes and New Infections, 2021 Sofosbuvir and daclatasvir have been used successfully since 2013 for hepatitis C treatment. It has been shown by different studies that sofosbuvir can inhibit RNA polymerase of other positive-strand RNA viruses including Flaviviridae and Togaviridae ...
M. Shabani +3 more
doaj +1 more source